González de Requena Daniel, Gallego Oscar, Corral Angélica, Jiménez-Nácher Inmaculada, Soriano Vincent
Pharmacology Unit, Hospital Carlos III, Madrid, Spain.
AIDS. 2004 Oct 21;18(15):2091-4. doi: 10.1097/00002030-200410210-00017.
We examined the influence of both efavirenz plasma concentrations and non-nucleoside reverse transcriptase (NNRTI) resistance mutations on the antiviral activity of efavirenz in patients experiencing early virological failure under nevirapine-containing regimens. Up to 41% of patients reach less than 50 copies/ml at 48 weeks. No association was found between the presence of NNRTI resistance mutations and virological outcome. Nevertheless, patients responding virologically and carrying NNRTI-resistant viruses had higher efavirenz levels than those who did not respond.
我们研究了依非韦伦血浆浓度和非核苷类逆转录酶（NNRTI）耐药突变对在含奈韦拉平方案下出现早期病毒学失败的患者中依非韦伦抗病毒活性的影响。高达41%的患者在48周时病毒载量降至低于50拷贝/毫升。未发现NNRTI耐药突变的存在与病毒学结果之间存在关联。然而，病毒学应答且携带NNRTI耐药病毒的患者的依非韦伦水平高于无应答者。
